Unknown

Dataset Information

Cost Effectiveness of Molecular Diagnostic Testing Algorithms for the Treatment Selection of Frontline Ibrutinib for Patients with Chronic Lymphocytic Leukemia in Australia.


ABSTRACT:

Background

Clinical indications for ibrutinib reimbursement in Australia should consider the inclusion of patients with chronic lymphocytic leukemia (CLL) harboring prognostically unfavorable TP53/IGHV genomic aberrations. This study assessed the cost effectiveness of five first-line treatment strategies in CLL for young (aged ≤ 65 years), fit patients without significant comorbidities: (1) no testing (fludarabine, cyclophosphamide and rituximab [FCR] for all), (2) test for del(17p) only, (3) test for TP53 gene mutation status, (4) test for TP53 and IGHV gene mutation status and (5) no testing (ibrutinib for all).

Method

A decision analytic model (decision tree and partitioned survival model) was developed from the Australian healthcare system perspective with a lifetime hor

SUBMITTER: Vu M 

PROVIDER: S-EPMC10761538 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature